Figure 7.

Effects of the selective CB₁ antagonist, SR141716 on visceral pain-related responses during repetitive non-noxious CRD ni rats (10 distensions at 20 mmHg). A, SR141716 (0.3 μmol/kg) or vehicle (1 ml/kg) was administered intravenously between distensions 5 and 6 of the non-noxious CRD protocol (arrow). The broken line represents the mean basal activity of the abdominal musculature between distensions. B, Overall response to CRD (area under the curve, AUC, before and after treatments, distensions 1–5 and 6–10, respectively) for the different experimental groups. Data are mean ± SEM of 12 animals per group. *p < 0.05 versus the response to CRD before treatment.